

SUMMARY

PROJECT UPDATES

GENEGUT

- 3RD GA IN BUDAPEST
- NEW FACTSHEET FOR PATIENTS

3rd General Assembly
September 12-13
Budapest, Hungary




GENEGUT



On 12-13 September, the GENEGUT consortium met in Budapest for its third General Assembly. It was a great opportunity to discuss the progress made during the first year and plan the next steps for developing an RNA-based therapy for Crohn's Disease.

The project has also published an online "Factsheet for patients", available on its website.



GlycanTrigger

- VIRTUAL STEERING COMMITTEE MEETING

meeting, focusing on IBD treatment advancements and understanding gut glycans' role in inflammation.

On 14 September, we joined the GlycanTrigger Steering Committee

miGut-Health

- ONE YEAR OF miGut-Health PROJECT
- VIRTUAL GA

The project's first anniversary is approaching: a good time to reflect on the work done so far.

Also, on 21 September the virtual miGut-Health General Assembly took place, where the project's progress was discussed.



FIBROTARGET

- VIRTUAL GENERAL ANNUAL MEETING (GAM)
- PARTNER'S UEG WEEK INSIGHTS

On 9 October, the virtual FIBROTARGET General Annual Meeting (GAM) discussed project updates across various work packages, including characterising fibrosis biomarkers, evaluating IBD inhibitors and initiating a clinical trial for fibrostenotic CD patients.

On a different note, FIBROTARGET's partner Motilent has shared their UEG Week insights & posters.

METHYLOMIC

- NEW MONTHLY INTERVIEWS



METHYLOMIC has started a brief monthly 3-questions interview around the project on its website. In its first edition, Professor Wouter de Jonge, from Amsterdam UMC, shares insights into his motivation, challenges and hopes for the project.

PROJECT UPDATES

GENEGUT'S 3RD GENERAL ASSEMBLY

Held in Budapest on 12-13 September, GENEGUT's GA marked a year of progress in their quest for an RNA-based therapy for Crohn's Disease.



SAB member Prof. Katie Whitehead contributed valuable insights into lipid nanoparticles for mRNA delivery to the pancreas.

The event concluded with sessions on early-career researchers and science communication, enhancing the project's impact and outreach.

During the two-day meeting hosted by GENEGUT partner CarboHyde, over 30 attendees from all nine partner organisations discussed RNA-based therapeutics and project updates. News from project management and scientific work packages highlighted significant progress, as mentioned by coordinator Prof. Caitriona O'Driscoll (UCC).

The assembly also included a session on regulatory guidelines for nucleic acid APIs, led by Prof. Dr. Csóka Ildikó from the University of Szeged, Hungary.

The second day focused on science communication, project dissemination and collaboration with EFCCA, laying the foundation for successful project exploitation.

Visit [GENEGUT's website](#) to learn more.

CELEBRATING 1 YEAR OF GENEGUT!



The GA coincided with the first anniversary of the project. To celebrate this milestone, a video was recorded featuring project coordinator Caitriona O'Driscoll and members of the consortium. Watch it [here!](#)



This project has received funding from the European Union (GA 101057491) and is supported by the Swiss State Secretariat for Education, Research and Innovation (SERI) under contract number 22.00119.

GENEGUT: FACTSHEET

Following a patient-centred approach, the project has now published online a “Factsheet for patients”.

The brochure summarises the most relevant information about GENEGUT, tailored to patients. It delves into details about the project, RNA-therapy, future clinical studies, and the involvement of EFCCA.

You can download it from the [GENEGUT website](#).




GlycanTrigger VIRTUAL STEERING COMMITTEE MEETING

On 14 September, we attended the virtual semi-annual Steering Committee meeting of GlycanTrigger.

The meeting focused on presenting an update on the progress achieved since the project initiation in January 2023.

The partners of the GlycanTrigger project convened virtually with representatives from the External Advisory Board, which provided project strategy guidance, evaluated progress,




assessed partner collaboration effectiveness, ensuring transparent information flow across project components advised on disseminating project results and materials.



This project is funded by the European Union under the Grant Agreement no. 101093997.



Approaching its one-year milestone, the miGut-Health project has made significant strides since its initiation in January 2023. These accomplishments encompass the identification of patient cohorts, the prioritisation of patient data collection, an ongoing examination of socio-psychological factors in IBD and the registration of a clinical study showcasing the efficacy of a prolonged dietary intervention in modifying intestinal inflammation in IBD cohorts.



The virtual General Assembly of the miGut-Health project, dedicated to preventive measures in IBD, took place on 21 September. During this event, each partner provided a complete progress update and discussed their upcoming areas of focus.



This project has received funding from the European Union and is supported by the Swiss State Secretariat for Education, Research and Innovation (SERI)

ONE YEAR OF miGut-Health PROJECT

The project's first anniversary has been an opportunity to take stock of the work done so far.

Regular online meetings, featuring guest speakers and insights from external experts, have played a pivotal role in ensuring effective communication and continuous learning, thus positioning the project on a promising trajectory.

The project has created a leaflet summarizing its work and objectives. You can download it from the miGut-Health website [here](#).

miGut-Health VIRTUAL GA


The virtual meeting had an active participation from the project partners.

EFCCA will collaborate with the Università Cattolica del Sacro Cuore in Milan, Italy, to actively engage people living with IBD and those at substantial risk of developing it in health and prevention initiatives.

For more details, visit [miGut-Health website](#).

FIBROTARGET VIRTUAL GENERAL ANNUAL MEETING

On 9 October, the FIBROTARGET virtual GAM took place.



The meeting served as a platform for project updates and involved the project's communication team and representatives from KU Leuven, including the Coordinator, Professor Séverine Vermeire, and Principal Investigator Professor Gianluca Matteoli.

Updates presented included fibrosis biomarker characterization, inhibitor evaluation for IBD, diagnostic pathway development and the start of a clinical trial for fibrostenotic CD patients, as

well as discussions on regulatory strategies and alignment with Fibrotarget's progress and goals.

Visit [FIBROTARGET's website](#) to know more about the project!

INSIGHTS FROM UEG WEEK



FIBROTARGET project shares partner Motilent's key insights from their posters and involvement in United European Gastroenterology (UEG) Week 2023 sessions. As they highlight, non-invasive imaging tools could help change the diagnostic and care landscape for individuals living with IBD. Read it on FIBROTARGET's [website](#).

 This project has received funding from the European Union's Horizon Europe programme under grant agreement No 101080523.

METHYLOMIC MONTHLY INTERVIEW

METHYLOMIC launches a new initiative with this monthly 3-questions interview on its website.

In this first installment, the person chosen has been Wouter de Jonge, professor of Experimental Neuro-Gastroenterology, Amsterdam UMC and co-leader of Work Package 2.

Professor De Jonge shares his motivation for joining the project,



which primarily stems from his interest in understanding the intricacies of the intestinal biology, and talks about the perspectives of the project to enhance the lives of Crohn's disease patients. Read the complete interview [here](#).

 This project has received funding from the European Union's Horizon Europe programme under grant agreement No 101095449.